CLSI announces the webinar “Verification of AST Methods for the Implementation of the Carbapenem and Cephalosporin Breakpoints,” which will take place on April 26, 2012, from 1:00–2:00 PM Eastern (US) Time.
CLSI Announces Webinar: Verification of AST Methods for the Implementation of the Carbapenem and Cephalosporin Breakpoints
Wayne, Pennsylvania, USA—March, 2012—The Clinical and Laboratory Standards Institute (CLSI) announces the webinar “Verification of AST Methods for the Implementation of the Carbapenem and Cephalosporin Breakpoints,” which will take place on April 26, 2012, from 1:00–2:00 PM Eastern (US) Time.
Each year, CLSI revises its informational supplement on performance standards for antimicrobial susceptibility testing (AST). In January 2012, CLSI published “Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement” (M100-S22), which contains carbapenem and cephalosporin breakpoints (or interpretive criteria) for Enterobacteriaceae that differ from the current US Food and Drug Administration (FDA) breakpoints. This is a challenge for laboratories because commercial AST devices are required to report results using the FDA (former) breakpoints. Therefore, laboratories that wish to implement the new breakpoints must perform an in-house validation study in order to meet the regulatory requirements of the Clinical Laboratory Improvement Amendments and any other approved accrediting body.
In this webinar, the host will discuss when a verification study is needed for implementing new breakpoints, why such a study is needed, and how the study is designed and conducted. The webinar speaker is Jean B. Patel, PhD, D(ABMM), Deputy Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention. The learning level for this class is intermediate.
At the end of this webinar, attendees will:
1. Explain when and why verification studies of their AST systems are needed for the implementation of new or revised susceptibility testing breakpoints.
2. Design a verification study for implementation of the breakpoint changes.
3. Describe how to perform a verification study to implement the breakpoint changes for the revised CLSI carbapenem and cephalosporin breakpoints.
Each webinar participant will receive one credit hour Continuing Education Credit. CLSI is an approved provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science P.A.C.E.® Program.
CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information, visit the CLSI website at www.clsi.org or call 610.688.0100.
# # #